Chimeric Therapeutics Shows Promise in Ovarian and Pancreatic Cancers
Chimeric Therapeutics Shows Promise in Ovarian and Pancreatic Cancers
Chimeric Therapeutics (ASX:CHM), an Australian company specialising in cell therapy, has reported significant in vitro findings for its chlorotoxin (CLTX) chimeric antigen receptor (CAR) NK cell therapy, CHM 1301. These preclinical results highlight the therapy's notable efficacy against ovarian and pancreatic cancers, suggesting potential advancements in cancer treatment.
專門從事細胞療法的澳大利亞公司Chimeric Therapeutics (ASX: CHM) 報告了其氯毒素 (CLTX) 嵌合抗原受體 (CAR) NK 細胞療法 CHM 1301 的重大體外發現。這些臨床前結果突顯了該療法對卵巢癌和胰腺癌的顯著療效，表明癌症治療可能取得進展。
CHM 1301 represents a fusion of Chimeric's existing assets, combining the recently successful CHM 1101 CLTX CAR T cell therapy with CHM 0201, an off-the-shelf NK cell platform. The resulting product is a next-generation CLTX CAR NK cell therapy.
CHM 1301 融合了 Chimeric 現有資產，將最近成功的 CHM 1101 CLTX CAR T 細胞療法與現成的 NK 細胞平台 CHM 0201 相結合。由此產生的產品是下一代 CLTX CAR NK 細胞療法。
In preclinical in vitro experiments involving human ovarian and pancreatic cancer models, CHM 1301 demonstrated promising results. Cell-killing efficacy against ovarian cancer increased by approximately 260% compared to first-generation CHM 0201 cells, while in pancreatic cancer, cell-killing efficacy surged by up to 300%.
在涉及人類卵巢癌和胰腺癌模型的臨床前體外實驗中，CHM 1301 顯示出令人鼓舞的結果。與第一代CHM 0201細胞相比，對卵巢癌的殺滅細胞功效提高了約260％，而在胰腺癌中，殺滅細胞的功效激增了300％。
These findings signify a substantial expansion of Chimeric's CLTX CAR therapies into the realm of solid tumors beyond glioblastoma, addressing unmet medical needs in the field of cancer treatment.
這些發現表明，Chimeric的CLTX CAR療法已大幅擴展到膠質母細胞瘤以外的實體瘤領域，解決了癌症治療領域未得到滿足的醫療需求。
Buoyed by these promising results, Chimeric is propelling the CHM 1301 program to the next stage of preclinical development, utilising the recently developed armoured NK cell platform, CHM 0301. This platform aims to further enhance cell potency and bolster resistance against the immunosuppressive microenvironment typically encountered in solid tumors.
在這些令人鼓舞的結果的推動下，Chimeric正在利用最近開發的裝甲NK細胞平台CHM 0301將CHM 1301計劃推向臨床前開發的下一階段。該平台旨在進一步增強細胞效力，增強對實體瘤中常見的免疫抑制微環境的抵抗力。
Jennifer Chow, CEO, and Managing Director of Chimeric Therapeutics, expressed her optimism regarding these developments, stating, "We are encouraged by the swift progress demonstrated by our next-generation CHM 1301 platform. This work underscores the potential synergy among Chimeric's existing assets, our ability to explore new disease areas, and the prospect of heightened efficacy with an off-the-shelf version of our CHM 1101 CAR."
Chimeric Therapeutics首席執行官兼董事總經理Jennifer Chow對這些發展表示樂觀，她說：“我們下一代CHM 1301平台所取得的迅速進展令我們感到鼓舞。這項工作凸顯了Chimeric現有資產之間的潛在協同作用、我們探索新疾病領域的能力以及現成版本的CHM 1101 CAR提高療效的前景。”
Chimeric's cost-effective collaboration with Dr. David Wald at Case Western Reserve University has played a pivotal role in achieving these milestones, enabling the company to expand its next-generation pipeline while maintaining a focus on its current clinical-stage assets.
Chimeric與凱斯西儲大學的戴維·沃爾德博士進行了具有成本效益的合作，在實現這些里程碑方面發揮了關鍵作用，使公司能夠擴大下一代產品線，同時保持對當前臨床階段資產的關注。
譯文內容由第三人軟體翻譯。